Sorrento Therapeutics Inc. [SRNE] Is Currently -1.65 below its 200 Period Moving Avg: What Does This Mean?


Sorrento Therapeutics Inc. [NASDAQ: SRNE] loss -1.65% or -0.04 points to close at $2.38 with a heavy trading volume of 6665903 shares. The company report on March 25, 2022 that Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that it has entered into a non-binding term sheet with B. Riley Principal Capital, LLC (“BRPC”), a subsidiary of B. Riley Financial, Inc. (Nasdaq: RILY, together with its affiliates, “B. Riley”) for a committed equity financing facility (the “Facility”) under which it would be able to sell up to $5 billion of its registered common stock over a five-year period. The Facility would become effective in connection with the closing of the previously announced pending merger with Vickers Vantage Corp I (“Vickers”). Scilex would not be obligated to utilize any of the $5 billion facility and would be able to enter other financing transactions. No warrants will be issued in connection with the Facility.

The term sheet contemplates that in connection with the closing of the merger with Vickers, Scilex would enter into definitive agreements with respect to the Facility. Scilex would be able to determine, in its sole discretion, the timing, dollar amount and floor price per share of each draw under the Facility, subject to certain conditions. Any resales of shares sold by Scilex to BRPC under the Facility will be made pursuant to a registration statement to be filed with the Securities and Exchange Commission (the “SEC”) following the closing of the merger.

It opened the trading session at $2.46, the shares rose to $2.4999 and dropped to $2.375, the range by which the price of stock traded the whole day. The daily chart for SRNE points out that the company has recorded -70.76% loss over the past six months. However, it is still -21.43% lower than its most recent low trading price.

If we look at the average trading volume of 8.44M shares, SRNE reached to a volume of 6665903 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Sorrento Therapeutics Inc. [SRNE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRNE shares is $21.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley Securities have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on January 21, 2021, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on SRNE stock.

The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.17, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 16.11. The Price to Book ratio for the last quarter was 9.52, with the Price to Cash per share for the same quarter was set at 0.35.

Trading performance analysis for SRNE stock

Sorrento Therapeutics Inc. [SRNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.18. With this latest performance, SRNE shares dropped by -8.11% in over the last four-week period, additionally sinking by -70.76% over the last 6 months – not to mention a drop of -69.82% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 42.86, with the RSI for the last a single of trading hit 45.29, and the three-weeks RSI is set at 40.33 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 2.90, while it was recorded at 2.46 for the last single week of trading, and 6.23 for the last 200 days.

Sorrento Therapeutics Inc. [SRNE]: A deeper dive into fundamental analysis

Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.20.

Sorrento Therapeutics Inc. [SRNE]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.

An analysis of insider ownership at Sorrento Therapeutics Inc. [SRNE]

There are presently around $225 million, or 27.70% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: BLACKROCK INC. with ownership of 21,775,865, which is approximately 4.352% of the company’s market cap and around 0.60% of the total institutional ownership; VANGUARD GROUP INC, holding 15,692,730 shares of the stock with an approximate value of $37.98 million in SRNE stocks shares; and STATE STREET CORP, currently with $35.32 million in SRNE stock with ownership of nearly 18.787% of the company’s market capitalization.

Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 119 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 11,095,796 shares. Additionally, 100 investors decreased positions by around 4,192,886 shares, while 49 investors held positions by with 77,749,322 shares. The mentioned changes placed institutional holdings at 93,038,004 shares, according to the latest SEC report filing. SRNE stock had 51 new institutional investments in for a total of 2,564,955 shares, while 38 institutional investors sold positions of 1,584,365 shares during the same period.